Lobby Watch: The Social Issues Research Centre by Miller, David & De Andrade, Marisa
BMJ | 6 March 2010 | VoluMe 340      511
OBSERVATIONS
 
LOBBY WATCH David Miller, Marisa De Andrade
The Social Issues Research Centre
The Social Issues Research Centre (SIRC) is  
an “independent, non-profit organisation” 
that says it carries out “balanced, calm and 
thoughtful” research on lifestyle issues such as 
drinking, diet, and pharmaceuticals  
(www.sirc.org). However, it may be perceived 
that the organisation acts more like a public 
relations agency for the corporations that fund 
its activities. These include Diageo, Flora, Coca-
Cola, GlaxoSmithKline, and Roche, among 
others. Although SIRC does publish this partial 
list of funders, it is not immediately apparent 
which company has sponsored which study. 
And in some instances this information is not 
included in media reports.
SIRC has produced guidelines for journalists 
on the reporting of science and health issues, 
but the guidelines include little on transparency 
or avoiding conflicts of interest. SIRC is not 
always transparent about its own funding. For 
example, it was commissioned by HRT Aware 
to produce a report that concluded that “well-
informed women” taking hormone replacement 
therapy are “benefiting” and feeling happier, 
healthier, and sexier. The research received 
widespread coverage in the broadsheet, tabloid, 
and broadcast media. Neither the press nor SIRC 
mentioned that HRT Aware was funded by drug 
companies, including Janssen-Cilag, Wyeth, 
Solvay, Servier, Organon, and Novo Nordisk. 
SIRC mentioned, on the back cover of the report, 
only that HRT Aware was “industry supported.”
SIRC’s science reporting guidelines focus 
on the exaggeration of risk by the media but 
have little to say about risks 
that may be underplayed 
by the media. SIRC is 
sceptical that there is 
such a thing as an obesity 
“epidemic,” which may 
fit well with the interests 
of funders such as  Coca-
Cola, Cadbury Schweppes, Masterfoods, 
and the Sugar Bureau. It has coined the term 
“riskfactorphobia” to suggest that we are too 
averse to risk, which fits the interests of the 
food companies as well as the raft of alcohol 
firms for which SIRC works. None of the reports 
mentioned in the foregoing paragraph contain 
information about the source of funding, so it is 
difficult to tell how “clients” feed into particular 
activities.
In some cases SIRC does say which 
corporation has sponsored its reports. Ebay 
funded a report on the “ebay generation”; Tio 
Pepe, a drinks company, funded one on dinner 
parties; the Prudential, an insurance company, 
one on risk; and pub chain owner Greene King 
on “the local.”
Although SIRC’s publicity material regularly 
uses the term “social scientists” to refer to its 
own staff, it uses the same personnel and office 
as a commercial market research company, 
MCM Research. SIRC’s codirectors, Peter Marsh 
and Kate Fox, work for both organisations. The 
MCM website used to ask: “Do your PR initiatives 
sometimes look too much like PR initiatives? 
MCM conducts social/psychological research 
on the positive aspects of your business. The 
results do not read like PR literature, or like 
market research data. Our reports are credible, 
interesting and entertaining in their own right. 
This is why they capture the imagination of the 
media and your customers.”
Recently, however, MCM has taken a lower 
profile. Its website now redirects to the SIRC 
one, and visitors are informed that the centre 
“has now taken over the task of hosting and 
publishing reports and materials conducted 
under the MCM Research name.”
Still, SIRC is taken seriously by some in 
government. It was recently commissioned 
to produce two independent reviews for an 
investigation by the Department for Children, 
Schools and Families of the commercialisation 
of childhood. The reports, published in late 
2009, oppose a public health approach that is 
based on population level measures, including 
the restriction of advertising or marketing. The 
conclusion that SIRC reached is that “the issues 
involved are very much more complex”—a 
position consistent with that advanced by 
elements of the food and advertising industries.
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Lobby Watch is a regular column that looks at the people and organisations that have an influence on how health care is 
delivered and on public health. It is put together with the help of the team at Strathclyde University who work on the Spin Profiles 
website (www.spinprofiles.org).  
SIRC produces guidelines for journalists on the reporting of science  
and health issues, but is it as independent as it is perceived to be? 
BMJ.COM pOLL ReSuLTS
Homoeopathy on the NHS
A recent poll on bmj.com asked: “Should 
homoeopathy be available on the NHS?” The 
question generated an unprecedented number 
of responses, in excess of 10 000; and 79% of 
respondents voted “No.” Unusually, more than 
50 respondents left a comment, and some of their 
thoughts make interesting reading.
“It won’t save the NHS any real money if 
homoeopathy is banished from the NHS, for an 
important role of homoeopathy in the NHS is to 
render treatment-satisfaction to subgroups of 
patients who have exhausted all the conventional 
options. Who’s going to take these patients then? 
Will the alternative to NHS homoeopathy be 
cheaper?” asks correspondent Sam. 
William House thinks homoeopathy should 
continue to be available on the NHS, for numerous 
reasons. He concludes: “We are undergoing a 
shift of power away from large institutions and 
corporations and towards the public and must 
listen to the public on this issue. Congratulations to 
government for doing so.”
Worm says: “Homoeopathy doesn’t work. Every 
single high-quality study shows this. The NHS 
should not be in the business of allocating valuable 
resources to pseudo-scientific wishful thinking. Go 
away, do some proper research, show effectiveness 
and then start asking the NHS to fund it.”
And Barry Desbrough suggests a fully integrated 
solution: “Placebo medication is OK, as long as 
it is not used in place of effective medication. It 
should be a heck of a lot cheaper though. Can’t the 
NHS make its own sugar pills and little bottles of 
water?”
The poll is now closed, but you can still 
participate in a discussion about homoeopathic 
remedies on doc2doc, the BMJ Group’s clinical 
community, at http://tinyurl.com/yjb9esr.
Also on doc2doc, the question “Would 
you change career after medical school?” 
(with accompanying poll) has sparked a lively 
discussion. Opinions range from “I’m eight years 
into this career now and am not likely to back down 
without a fight” (Merys Jones) to “I really do believe 
medicine is worth leaving only if there’s something 
you’d much rather do” (DC).
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